ArticleInternational journal of clinical and experimental medicine2014
Reduced E-Cadherin expression is a prognostic biomarker of non-small cell lung cancer: a meta-analysis based on 2395 subjects.
Article in International journal of clinical and experimental medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Upregulated N-cadherin expression is associated with poor prognosis in epithelial-derived solid tumours: A meta-analysis.European journal of clinical investigation · 2018Pooled it
- LncCDH5-3:3 Regulates Apoptosis, Proliferation, and Aggressiveness in Human Lung Cancer Cells.Cells · 2022Article
- Engineered Bacteriorhodopsin May Induce Lung Cancer Cell Cycle Arrest and Suppress Their Proliferation and Migration.Molecules (Basel, Switzerland) · 2021Article
- Article
- SATB1 protein is associated with the epithelial‑mesenchymal transition process in non‑small cell lung cancers.Oncology reports · 2021Article
- Current progress and mechanisms of bone metastasis in lung cancer: a narrative review.Translational lung cancer research · 2021Review
- Diversity of Vascular Niches in Bones and Joints During Homeostasis, Ageing, and Diseases.Frontiers in immunology · 2021Review
- The investigation of transcriptional repression mediated by ZEB2 in canine invasive micropapillary carcinoma in mammary gland.PloS one · 2019Article
- Pepsin promotes IL-8 signaling-induced epithelial-mesenchymal transition in laryngeal carcinoma.Cancer cell international · 2019Article
- Down Regulation of the Expression of ELMO3 by COX2 Inhibitor Suppresses Tumor Growth and Metastasis in Non-Small-Cell Lung Cancer.Frontiers in oncology · 2019Article
- The contrasting roles of inflammasomes in cancer.American journal of cancer research · 2018Review
- MiR-200c suppresses the migration of retinoblastoma cells by reversing epithelial mesenchymal transition.International journal of ophthalmology · 2017Article
- Progress in the research on the mechanism of bone metastasis in lung cancer.Molecular and clinical oncology · 2016Article
- MicroRNA profiling of cisplatin-resistant oral squamous cell carcinoma cell lines enriched with cancer-stem-cell-like and epithelial-mesenchymal transition-type features.Scientific reports · 2016Article
- Differentially Expressed MicroRNAs in Meningiomas Grades I and II Suggest Shared Biomarkers with Malignant Tumors.Cancers · 2016Article
- Annexin A3 Knockdown Suppresses Lung Adenocarcinoma.Analytical cellular pathology (Amsterdam) · 2016Article
- Expression of calcium sensing receptor and E-cadherin correlated with survival of lung adenocarcinoma.Thoracic cancer · 2015Article
- S100P interacts with integrin α7 and increases cancer cell migration and invasion in lung cancer.Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePrevious studies related to the prognostic value of E-Cadherin expression on non-small cell lung cancer (NSCLC) were inconsistent. The present study aimed to evaluate the relation between E-Cadherin expression and the prognosis of NSCLC.
methodsWe performed a meta-analysis based on 14 studies including 2395 NSCLC patients. Literature retrieval, data extraction, and meta-analyses were performed according to the Revman 5.0 guidelines. We utilized the fixed-effect model to pool the HR according to the test of heterogeneity in the meta-analysis.
resultsA total of 14 eligible studies including 2395 NSCLC patients were analyzed. In total, 51.2% of the patients were considered as having reduced expression of E-Cadherin according to the authors' cutoff. The pooled hazard ratio (HR) of reduced expression of E-Cadherin for overall survival (OS) was 1.19 (95% CI: 1.01 to 1.40, P=0.04), showing a worse survival when E-Cadherin expression is decreased.
conclusionPatients with reduced expression of E-cadherin have a poorer OS compared with those with normal or high expression of E-cadherin.
Indexed as
Identifiers
25550954PMC4276212W307054266What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.